December 10, 2019
ArcticZymes is pleased to announce a new and novel member of the Salt Active Nuclease (SAN) portfolio; M-SAN High Quality. The new SAN enzyme builds on the highly demanded SAN High Quality nuclease serving the bio-manufacturing market segment. While SAN HQ is designed to work in the high salt concentration range, M-SAN HQ has been developed to offer the optimal solution for removal of nucleic acids at physiological salt conditions. High activity at physiological salt conditions is very relevant in many bioprocessing and biomanufacturing workﬂows in which currently available nucleases are ineffective. Thus M-SAN HQ can help avoid unnecessary steps in the workflows and by doing so increase efficiencies and the utility of the enzyme.
“We are excited to expand our product portfolio within the bio-manufacturing markets where our unique technologies can have a major impact. The new edition to our SAN products can greatly help both new and current customers” says Dr. Jethro Holter, Interim CEO, Biotec Pharmacon.
ArcticZymes is currently developing an ELISA-kit for M-SAN which is expected to be launched within 2020. Prototypes of the kit will be made available for testing by key customers prior to launch. M-SAN will be available for shipping from January 2020. Request a quote today here or by contacting your local Business Development Manager.
To learn more about M-SAN, visit the technology page, or check out the brochure.
ArcticZymes AS is pleased to announce the launch of HL-dsDNase Glycerol-free Triton FREE. This launch is a continuing step towards maintaining a completely EU REACH compliant product portfolio after Triton X-100 becomes subject to authorisation in January 2021. The convenient glycerol-free formulation is suitable for lyophilization and automated processes. The new formulation offers the same advantages as HL-dsDNase, such as strong preference for double stranded DNA and heat inactivation at low temperatures.
HL-dsDNase Glycerol-free Triton FREE is available for shipping. You can request a quote by contacting your local Business Development Manager or using this form.
In a paper published in Nature Biotechnology, Justin O’Grady’s group at the Quadram Institute in Norwich (UK), a leading entity on molecular diagnostics of pathogens, has used HL-SAN from ArcticZymes as a critical component in a novel and rapid method for diagnosing bacterial lower respiratory infections (LRIs).
The current gold standard for diagnosing bacterial LRIs typically requires 48 – 72 hours to identify the pathogen. Waiting 2 – 3 days before initiating targeted antibiotic treatment is not an option when facing severe infections, and the decision is usually made to initiate treatment with broad-spectrum antibiotics immediately. This practice comes with the risk of evolving new antibiotic resistant bacteria. To avoid over-use of antibiotics and allow targeted treatment, new technologies are needed which within hours can identify the infection-causing pathogen. This is particularly relevant for respiratory tract infections, as they account for 60% of the antibiotics prescribed in general practice in the UK.
Metagenomics is a method where all the DNA in a specific sample is sequenced. This allows not only detection of rare and unexpected pathogens but can also offer information about any antibiotic resistances of the pathogens. Metagenomic sequencing of human samples can be difficult due to the vast amount of DNA originating from the patient compared to the very small amounts of pathogen DNA in the sample. To avoid this problem, the patient DNA must be removed prior to bacterial cell lysis and sequencing.
In their article, Charalampous et al. describe how using a detergent at very high salt concentrations makes human DNA more accessible for nuclease-digestion while keeping the pathogens in the sample intact. However, using nucleases to remove unwanted DNA at very high salt concentrations is generally not effective due to their low tolerance to salt. HL-SAN from ArcticZymes, a nuclease originating from the saline marine environments in the Arctic, actually prefers high salt conditions and thereby provides a perfect match for this approach.
By using HL-SAN as a key component in their work, the researchers were able to use metagenomics to identify LRI-causing pathogens as well as accurately detect resistance against antibiotics within a time span of 6 hours. This allows targeted treatment to begin within a working day.
ArcticZymes is proud to learn that one of our products can be used to reduce the threat multi-resistant bacteria is posing to the public. We also acknowledge that metagenomics holds great promise for diagnosis and analysis on a large variety of sample material. It is envisioned that HL-SAN can be an important component in technologies targeting the growing metagenomic diagnosis market.
Reference: Charalampous, T., et al. (2019). “Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection.” Nature Biotechnology 37(7): 783-792.
A preprint of the paper is available here.
ArcticZymes is pleased to announce the launch of SAN HQ Triton FREE. The new formulation offers the same advantages as SAN HQ, such as highly effective DNA digestion at high salt conditions, extensive quality control testing and compatibility with SAN HQ ELISA to verify the clearance of the enzyme downstream, while also ensuring EU REACH compliance.
The new formulation has already been tested by select partners and customers within the fields of viral vector and vaccine production.
SAN HQ Triton FREE will be available for shipping shortly. You can request a quote by contacting your local Business Development Manager or using this form.